Paul Song
Chief Executive Officer NKGen Biotech
Seminars
Friday 12th December 2025
Exploring Natural Killer Cell Immunotherapeutics to Reduce Neuroinflammation in Alzheimer’s & FTD
11:00 am
- Deciphering Troculeucel’s mechanism of action in reducing CSF neuroinflammatory and protein biomarkers
- Ensuring auto-activated T cell targeting without affecting resting T cells to fundamentally address neuroinflammation
- Reviewing the early clinical efficacy of Troculeucel in AD and FTD patients
